Scrip
Genentech withdraws psoriasis drug Raptiva in US over PML risk
09 April 2009
Katie McQue
Genentech is to withdraw its psoriasis therapy Raptiva (efalizumab) in the US based on its association with an increased risk of developing progressive multifocal leucoencephalopathy (PML), a rare and potentially fatal brain infection.
Three patients taking the monoclonal antibody therapy were...
Please Login to read the full article.
09 April 2009
Katie McQue
Three patients taking the monoclonal antibody therapy were...
Please Login to read the full article.
RELATED CONTENT
NEWS
- CHMP recommends guidance to manage risk of PML with Biogen's Tysabri
- Acorda/Biogen Idec's Ampyra becomes first US FDA-approved drug to improve walking in MS
- US FDA approves Roche's Actemra for previously treated RA
- US FDA approves Roche's Actemra for previously treated RA - update
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
